Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Venture Capital Survey Paints Bleak Portrait

Executive Summary

A poll of 100 life science VCs reveals fears of industry contraction, increased importance of corporate investors, and attitudes on regulators, therapeutic areas and new investment models.

You may also be interested in...



Mid-To-Late-Stage Investor Longitude Capital Closes $385M Second Fund

A history of strong returns from the firm, which backs both private and public health care companies, compelled existing investors to return for a new fund. Still, Longitude retained a placement agent to find new limited partners as an “insurance policy.”

No Obvious Prescription For Biopharma Investors

In our second annual Life Science VC Survey, biopharma investors continue to look to oncology and rare disease, while their cold shoulder toward metabolic disease seems to be warming. Even though most agree the traditional biotech funding model is broken, our participants are far from convinced that new models such as asset-based financing are the answer.

Corporate Venture Eyes The Early Stage

In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel